Epidemiology of Venous Thromboembolism

Clive Kearon

doi:10.1055/s-2001-14668

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2001; 01(1): 007-026
DOI: 10.1055/s-2001-14668

Epidemiology of Venous Thromboembolism

Clive Kearon

McMaster Clinic, Henderson General Hospital, Hamilton, Ontario, Canada

Abstract

ABSTRACT

The annual incidence of diagnosed venous thromboembolism (VTE) is 1 to 2 events per 1000 of the general population. VTE is very uncommon before age 20 years and, after 40 years of age, the incidence about doubles with each decade. Over half of episodes of VTE are deep vein thrombosis (DVT), and three quarters are first episodes. The incidence of VTE is similar in men and women and lower in Asians than it is in Caucasians or Africans. Hereditary risk factors include the factor V Leiden mutation; the G20210A prothrombin gene mutation; and deficiencies of protein C, protein S, and antithrombin. Hyperhomocysteinemia and elevated levels of factors I, VIII and XI, which may be hereditary and/or acquired, are also risk factors. Acquired risk factors include malignancy, hospitalization, surgery, venous trauma, immobilization, estrogen therapy, pregnancy, and the antiphospholipid antibodies. Risk factors for a first episode of VTE are generally also risk factors for recurrence, although the associated relative risk for thrombosis may differ for a first and subsequent event.

KEYWORD

Venous thromboembolism - deep vein thrombosis - pulmonary embolism - risk factors - epidemiology

Full Text

References

REFERENCES

1 Hull R D, Hirsh J, Carter C J. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med . 1983; 98 891-899
2 Doyle D J, Turpie A GG, Hirsh J. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med . 1987; 107 441-445
3 Huisman M V, Buller H R, ten Cate J. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest . 1989; 95 498-502
4 Kruit W HJ, de Boer C A, Sing A K, van Roon F. The significance of venography in the management of patients with clinically suspected pulmonary embolism. J Intern Med . 1991; 230 333-339
5 Kearon C, Salzman E, Hirsh J. Epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman R, Hirsh J, Marder JV, Clowes AW, George JN, eds. Hemostasis and Thrombosis Philadelphia: Lippincott Williams & Wilkins 2001
6 Stein P D, Henry J W. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest . 1995; 108 978-981
7 Bell W R, Simon T L. Current status of pulmonary embolic disease: pathophysiology, diagnosis, prevention, and treatment. Am Heart J . 1982; 103 239-261
8 Hull R D, Raskob G E, Coates G, Panju A A, Gill G J. A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med . 1989; 149 2549-2555
9 Stein P D, Terrin M L, Hales C A. Clinical, laboratory, roetgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest . 1991; 100 598-603
10 Morganthaler T I, Ryu J H. Clinical characterisitics of fatal pulmonary embolism in a referral hospital. Mayo Clin Proc . 1995; 70 417-424
11 Kahn S R, Solymoss S, Lamping D L, Abenhaim L. Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life. J Gen Intern Med . 2000; 15 425-429
12 Wells P S, Hirsh J, Anderson D R. Accuracy of clinical assessment of deep-vein thrombosis. Lancet . 1995; 345 1326-1330
13 Wells P S, Hirsh J, Anderson D R. A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnosis process. J Intern Med . 1998; 243 15-23
14 Wells P S, Ginsberg J S, Anderson D R. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med . 1998; 129 997-1005
15 Wells P S, Anderson D R, Rodger M. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost . 2000; 83 416-420
16 Kearon C, Julian J A, Newman T E, Ginsberg J S, for the McMaster Diagnostic Imaging Practice Guidelines Initiative. Non-invasive diagnosis of deep vein thrombosis. Ann Intern Med . 1998; 128 663-677
17 Kearon C, Hirsh J. The diagnosis of pulmonary embolism. Haemostasis . 1995; 25 72-87
18 Ginsberg J S, Wells P S, Kearon C. Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. Ann Intern Med . 1998; 129 1006-1011
19 Lensing A WA, Hirsh J. ¹²⁵I-fibrinogen leg scanning: reassessment of its role for the diagnosis of venous thrombosis in post-operative patients. Thromb Haemost . 1993; 69 2-7
20 Anderson F A, Wheeler H B, Goldberg R J. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med . 1991; 151 933-938
21 Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis with a defined urban population. J Intern Med . 1992; 232 155-160
22 Silverstein M D, Heit J A, Mohr D N, Petterson T M, O'Fallen W M, Melton J. Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med . 1998; 158 585-593
23 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost . 2000; 83 657-660
24 Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg . 1991; 78 849-852
25 Sandler D A, Martin J F. Autopsy-proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. J R Soc Med . 1989; 82 203
26 Rasmussen M S, Wille-Jorgensen P, Jorgensen L N. Postoperative fatal pulmonary embolism in a general surgical department. Am J Surg . 1995; 169 214-216
27 Clagett G P, Reisch J S. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg . 1988; 208 227-240
28 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med . 1988; 318 1162-1173
29 Kniffin Jr D W, Baron J A, Barrett J, Birkmeyer J D, Anderson F A. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med . 1994; 154 861-866
30 Ridker P M, Robert J G, Miletich J P, Goldhaber S Z, Stampfer M J, Hennekens C H. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of Factor V Leiden mutation. Ann Intern Med . 1997; 126 528-531
31 Clarke-Pearson D L, DeLong E R, Synan I S, Coleman R E, Creasman W T. Variables associated with postoperative deep venous thrombosis: a prospective study of 411 gynecology patients and creation of a prognostic model. Obstet Gynecol . 1987; 69 146-150
32 Veth G, Meuwissen O A Th J, van Houwelingen C H, Sixma J J. Prevention of postoperative deep vein thrombosis by a combination of subcutaneous heparin with subcutaneous dihydroergotamine or oral sulphinpyrazone. Thromb Haemost . 1985; 54 570-573
33 Wille-Jorgensen P, Ott P. Predicting failure of low-dose prophylactic heparin in general surgical procedures. Surg Gynecol Obstet . 1990; 171 126-130
34 Flordal P A, Bergqvist D, Ljungstrom K G, Torngren S. Clinical relevance of the fibrinogen uptake test in patients having general abdominal surgery-relation to major thromboembolism and mortality. Thromb Res . 1995; 80 491-497
35 Brandjes D PM, ten Cate W J, Buller H R. Pre-surgical identification of the patient at risk for developing venous thromboembolism post-operatively. Acta Chir Scand . 1990; 18-21 (18-21)
36 Eriksson B I, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet . 1996; 347 635-639
37 Eriksson B I, Wille-Jorgensen P, Kalebo P. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med . 1997; 337 1329-1335
38 White R H, Romano P S, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med . 1998; 158 1525-1531
39 Lilienfeld D E, Chan E, Ehland J, Godbold J H, Landrigan P J, Marsh G. Mortality from pulmonary embolism in the United States: 1962 to 1984. Chest . 1990; 98 1067-1072
40 Butler C M, Cotton L T, Roberts V C. Mortality trends from venous thrombosis and embolism in England and Wales. Lancet . 1983; 2 1314
41 Flordal P A, Bergqvist D, Burmark U S, Ljungström K G, Törngren S. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. Eur J Surg . 1996; 162 783-789
42 White R H, Zhou H, Romano P S. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med . 1998; 128 737-740
43 Hassan M A, Rahman I A. Prostatectomy and deep vein thrombosis in Sudanese patients. Br J Surg . 1974; 61 650
44 Kim Y-H, Suh J-S. Low incidence of deep-vein thrombosis after cementless total hip replacement. J Bone Joint Surg . 1988; 70A 878
45 Chumnijarakij T, Poshyachinda V. Postoperative thrombosis in Thai women. Lancet . 1975; 1 1357
46 Thomas W A, Davies J NP, O'Neal R M, Dimakulangan A A. Incidence of myocardial infarction correlated with venous and pulmonary thrombosis and embolism. Am J Cardiol . 1960; 5 41
47 Gore I, Hirst A E, Tanaka K. Myocardial infarction and thromboembolism. Arch Intern Med . 1964; 113 323
48 Hull R, Raskob G, Pineo G. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med . 1993; 329 1370-1376
49 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden. Lancet . 1995; 346 1133-1134
50 Ridker P M, Miletich J P, Hennekens C H, Buring J E. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA . 1997; 277 1305-1307
51 Pepe G, Rickards O, Vanegas O C. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost . 1997; 77 329-331
52 Rosendaal F R, Doggen C JM, Zivelin A. Geographic distribution of the 20210 G to a prothrombin variant. Thromb Haemost . 1998; 79 706-708
53 Grady D, Wenger N K, Herrington D, Khan S, Furberg C, Hunninghake D. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med . 2000; 132 689-696
54 Anderson F A, Wheeler H B, Goldberg R J, Hosmer D W, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med . 1992; 152 1660-1664
55 Harris W, Sledge C B. Total hip and total knee replacement. N Engl J Med . 1990; 323 725-731
56 Lieberman J R, Geerts W H. Prevention of venous thromboembolism after total hip and knee arthoplasty. J Bone Joint Surg . 1994; 76-A 1239-1250
57 Robinson K S, Anderson D R, Gross M. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the Post-Arthoplasty Screening Study. A randomized, controlled trial. Ann Intern Med . 1997; 127 439-445
58 Leclerc J R, Gent M, Hirsh J, Geerts W, Ginsberg J S. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin. Arch Intern Med . 1998; 158 873-878
59 Colwell Jr W C, Collis D K, Paulson R. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. J Bone J Surg . 1999; 81-A 932-940
60 Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet . 2000; 355 1295-1302
61 Clagett G P, Anderson F A, Heit J, Levine M N, Wheeler H B. Prevention of venous thromboembolism. Chest . 1995; 312S-334S (312S-334S)
62 Stamatakis J D, Kakkar V V, Sagar S, Lawrence D, Nairn D, Bentley P G. Femoral vein thrombosis and total hip replacement. Br Med J . 1977; 2 223-225
63 Cruickshank M K, Levine M N, Hirsh J. An evaluation of impedance plethysmography and ¹²⁵I-fibrinogen leg scanning in patients following hip surgery. Thromb Haemost . 1989; 62 830-834
64 Field E S, Nicolaides A N, Kakkar V V, Crellin R Q. Deep vein thrombosis in patients with fractures of the femoral neck. Br J Surg . 1972; 59 377
65 Modig G, Hjelmstedt A, Sahlstedt B, Maripuu E. Comparative influence of epidural and general anesthesia on deep venous thrombosis in pulmonary embolism after total hip replacement. Acta Chir Scand . 1981; 147 125
66 Demers C, Marcoux S, Ginsberg J S, Laroche F, Cloutier R, Poulin J. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med . 1998; 158 47-50
67 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J . 1994; 308 235-246
68 Heatley R V, Hughes L E, Morgan A. Preoperative or postoperative deep vein thrombosis. Lancet . 1976; 1 437-439
69 Geerts W H, Code K I, Jay R M, Chen E, Szalai J P. A prospective study of venous thromboembolism after major trauma. N Engl J Med . 1994; 331 1601-1606
70 Green D, Lee M Y, Ito V Y. Fixed-versus adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury. JAMA . 1988; 260 1255-1258
71 Green D, Lee M Y, Lim A C. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med . 1990; 113 571-574
72 Gallus A S, Nurmohammed M, Kearon C, Prins M. Thromboprophylaxis in non-surgical patients: who, when and how?. Haemostasis . 1998; 71-82 (71-82)
73 Lindblad B, Sternby N H, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J . 1991; 302 709-711
74 Gårdlund Bft H P S G. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet . 1996; 347 1357-1361
75 Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. Assessment of short term anticoagulant administration after cardiac infarction. Br Med J . 1969; 1 335-342
76 Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction: relation of therapeutic benefit to patient's age, sex and severity of infarction. JAMA . 1972; 222 541-548
77 Veterans Administration. Anticoagulants in acute myocardial infarction. JAMA . 1973; 225 724-729
78 Nicolaides A N, Kakkar V V, Reney J TG. Myocardial infarction and deep-vein thrombosis. Br Med J . 1971; 1 432-434
79 Murray T S, Lorimer A R, Cox F C, Lawrie T DV. Leg-vein thrombosis following myocardial infarction. Lancet . 1970; 2 792
80 Kotilainen M, Ristola P, Ikkala E, Pyorala K. Leg-vein thrombosis after acute myocardial infarction. Ann Clin Res . 1973; 5 365
81 Simmons A V, Sheppard M A, Cox A F. Deep venous thrombosis after myocardial infarction: predisposing factors. Br Heart J . 1973; 35 623
82 Anderson G M, Hull E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J . 1950; 39 697
83 Harvey W P, Finch C A. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med . 1950; 242 208-211
84 Pahor M, Guralnik J M, Havlik R J. Alcohol consumption and risk of deep venous thrombosis and pulmonary embolism in older persons. J Am Geriatr Soc . 1996; 44 1030-1037
85 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both or neither among 19435 patients with acute ischaemic stroke. Lancet . 1997; 349 1569-1581
86 CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin in 20,000 patients with acute ischaemic stroke. Lancet . 1997; 349 1641-1649
87 Sandercock P AG, van der Belt A, Lindley R, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomized trials. J Neurol Neurosurg Psychiatry . 1993; 56 17-25
88 Turpie A GG, Levine M N, Hirsh J. Double blind randomised trial of Org 10172 low-molecular-weight heparinoid in the prevention of deep vein thrombosis in thrombotic stoke. Lancet . 1987; 1 523-526
89 Warlow C, Ogston D, Douglas A S. Deep vein thrombosis of the legs after strokes. Br Med J . 1976; 1 1178
90 Prins M H, Hettiarachchi R JK, Lensing A WA, Hirsh J. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see?. Thromb Haemost . 1997; 78 121-125
91 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med . 2000; 342 1953-1958
92 Baron J A, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet . 1998; 351 1077-1080
93 Sorensen H T, Mellemkjaer L, Steffensen F H, Olsen J H, Nielsen G L. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med . 1998; 338 1169-1173
94 Rance A, Emmerich J, Guedj C, Fiessinger J-N. Occult cancer in patients with bilateral deep-vein thrombosis. Lancet . 1997; 350 1448-1449
95 Prandoni P, Lensing A WA, Piccioli A, Bagatella P, Girolami A. Ultrasonography of contralateral veins in patients with unilateral deep-vein thrombosis. Lancet . 1998; 352 786
96 Hutten B A, Prins M, Gent M, Ginsberg J, Tijssen J, Buller H. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol . 2000; 18 3078-3083
97 Prandoni P, Lensing A WA, Cogo A. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med . 1996; 125 1-7
98 White R H, Zhou H, Romano P S. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med . 1998; 158 1005-1010
99 Walsh J J, Bonnar J, Wright F W. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecologic surgery using labelled fibrinogen-phlebography and lung scanning. J Obstet Gynecol Br Commonw . 1974; 81 311
100 Rosenberg L, Evans M, Pollack A V. Prophylaxis of postoperative calf muscle stimulation: a controlled clinical trial. Br Med J . 1975; 1 649
101 Pineo G F, Brain M C, Gallus A S. Tumors, mucus production and hypercoagulability. Ann NY Acad Sci . 1974; 230 262
102 Kakkar V V, Howe C T, Nicolaides A N, Renney J T, Clarke M B. Deep vein thrombosis of the leg: Is there a ``high risk'' group?. Am J Surg . 1970; 120 527-530
103 Gallus A. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost . 1997; 78 126-132
104 Levine M N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost . 1997; 78 133-136
105 Levine M N, Gent M, Hirsh J. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med . 1988; 318 404-407
106 Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet . 1998; 351 1451-1467
107 Pritchard K I, Paterson A HG, Paul N A, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol . 1996; 14 2731-2737
108 Saphner T, Tormey D C, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol . 1991; 9 286-294
109 Fisher B, Redmond C, Legault-Poisson. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 years and older with tumours responsive to tamoxifen: results from the national surgical adjuvant breast and bowel project B16. J Clin Oncol . 1990; 8 1005-1018
110 Rifkin S E, Green S, Metch B. Adjuvant CMFVP versus tamoxifen evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumours. J Clin Oncol . 1994; 12 2078-2085
111 Veronesi U, Maisonneuve P, Costa A. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Lancet . 1998; 352 93-97
112 Fisher B. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst . 1998; 90 1371-1388
113 Macklon N S, Greer I A. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J . 1996; 41 83-86
114 McColl M D, Ramsay J E, Tait R C. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost . 1997; 78 1183-1188
115 Rutherford S, Montoro M, McGhee W, Strong T. Thromboembolic disease associated with pregnancy: an 11 year review. Am J Obstet Gynecol . 1991; 286 (286)
116 Briet E, van der Meer J M F, Rosendaal F R, Houwing-Duistermaat J J, van Houwelingen C H. The family history and inherited thrombophilia. Br J Haematology . 1994; 87 348-352
117 Vandenbroucke J P, Koster T, Briet E, Reitsma P H, Bertina R M, Rosendaal F R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet . 1994; 344 1453-1457
118 Ginsberg J, Brill-Edwards P, Burrows R F. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost . 1992; 67 519-520
119 de Boer K, Buller H R, ten Cate W J, Levi M. Deep vein thrombosis in obstetric patients: diagnosis and risk factors. Thromb Haemost . 1992; 67 4-7
120 Bokarewa M I, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol . 1996; 92 473-478
121 Friederich P W, Sanson B J, Simioni P. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med . 1996; 125 955-960
122 Middeldorp S, Henkens C MA, Koopman M MW. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med . 1998; 128 15-20
123 Cumming A M, Tait R C, Fildes S, Yoong A, Keeney S, Hay C RM. Development of resistance to activated protein C during pregnancy. Br J Haematol . 1995; 90 725-727
124 Schlit A F, Col-De Beys C, Moriau M, Lavenne- Pardonge E. Acquired activated protein C resistance in pregnancy. Thromb Res . 1996; 84 203-206
125 Clark P, Brennand J, Conkie J A, McCall F, Greer I A, Walker I D. Activated protein C sensitivity, protein C, Protein S and coagulation in normal pregnancy. Thromb Haemost . 1998; 79 1166-1170
126 Mathonnet F, De Mazancourt P, Bastenaire B. Activated protein C sensitivity ratio in pregnant women at delivery. Br J Haematol . 1996; 92 244-246
127 Woodhams B J, Candotti G, Shaw R, Kernoff P B. Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Thromb Res . 1989; 55 99-107
128 Toglia M R, Weg J G. Venous thromboembolism during pregnancy. N Engl J Med . 1996; 335 108-114
129 Goldhaber S Z, Grodstein F, Stampfer M J. A prospective study of risk factors for pulmonary embolism in women. JAMA . 1997; 277 642-645
130 Hansson P O, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: ``the study of men born in 1913''. Arch Intern Med . 1999; 159 1886-1890
131 Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboembolic disease: a case control study. Chest . 1999; 115 440-444
132 Cogo A, Bernardi E, Prandoni P. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med . 1994; 154 164-167
133 Becker J, Borgstrom S, Saltzman G-F. Occurrence and course of thrombosis following prostatectomy. Acta Radiol Diagn . 1970; 10 513
134 Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med . 1999; 130 643-650
135 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet . 1992; 340 873-876
136 Schulman S, Rhedin A-S, Lindmarker P. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med . 1995; 332 1661-1665
137 Levine M N, Hirsh J, Gent M. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost . 1995; 74 606-611
138 Pini M, Aiello S, Manotti C. Low molecular weight heparin versus warfarin the prevention of recurrence after deep vein thrombosis. Thromb Haemost . 1994; 72 191-197
139 Kearon C, Gent M, Hirsh J. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med . 1999; 340 901-907
140 Schulman S, Granqvist S, Holmstrom M. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med . 1997; 336 393-398
141 Schulman S. Optimal duration of oral anticoagulant therapy in venous thromboembolism. Thromb Haemost . 1997; 78 693-698
142 Lindmarker P, Schulman S. The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. The DURAC Trial Study Group. J Intern Med . 2000; 247 601-606
143 Tans G, Curvers J, Middeldorp S. A randomized cross-over study on the effects of levonorges. Thromb Haemost . 2000; 84 15-21
144 Meijers J C, Middeldorp S, Tekelenburg W. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost . 2000; 84 9-14
145 Middeldorp S, Meijers J C, van den Ende E A. Effects on coagulation of levonorges. Thromb Haemost . 2000; 84 4-8
146 Rosing J, Middeldorp S, Curvers J. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet . 1999; 354 2036-2040
147 Fuertes-de la Haba A, Curet J O, Pelegrina I, Bangdiwala I. Thrombophlebitis among oral and non-oral contraceptive users. J Reprod Med . 1971; 38 259-263
148 Records Units and Research Advisory Service of the Royal College of General Practitioners. Oral contraception and thrombo-embolic disease. J R Coll Gen Pract . 1967; 13 267-279
149 Pettiti D B, Wingerd J, Pellegrin F, Ramcharan S. Oral contraceptives, smoking, and other factors in relation to risk of venous thrombotic disease. Am J Epidemiol . 1978; 108 480-485
150 Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J . 1986; 292 526
151 Royal College of General Practioners' Oral Contraceptive Study. Oral contraceptives, venous thrombosis, and varicose veins. J R Coll Gen Pract . 1978; 28 393-399
152 Grodstein F, Stampfer M J, Goldhaber S Z. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet . 1996; 348 983-987
153 Porter J B, Hunter J R, Jack H, Stergachis A. Oral contraceptives and non-fatal vascular disease. J Am Coll Obstet Gynecol . 1985; 66 1-4
154 Porter J B, Hunter J R, Danielson D A, Jick H, Stergachis A. Oral contraceptives and non-fatal vascular disease-recent experience. Obstet Gynecol . 1982; 59 299-302
155 Helmrich S P, Piper J M, Kaufman D W, Strom B, Shaprio S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol . 1987; 69 91-95
156 Vessey M P, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J . 1968; 2 199-205
157 Vessey M P, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. Br Med J . 1969; 2 651-657
158 Boston Collaborative Drug Surveillance Programme. Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours. Lancet . 1973; 1 1399-1404
159 Stolley P D, Tonascia J A, Tockman M S, Sartwell P E, Rutledge A H, Jacobs M P. Increased risk of thrombosis due to oral contraceptives. Am J Epidemiol . 1975; 102 197-208
160 Maguire M G, Tonascia J A, Sartwell P E, Stolley P D, Tockman M S. Increased risk of thrombosis due to oral contraceptives: a further report. Am J Epidemiol . 1979; 110 188-195
161 Sartwell P E, Masi A T, Arthes F G, Greene G R, Smith H E. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol . 1969; 90 365-380
162 Valla D, Le M G, Poynard T, Zucman N, Rueff B, Benhamou J-P. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives: a case-control study. Gastroenterology . 1986; 90 807-811
163 Spitzer W O, Lewis M A, Heinemann L AJ, Thorogood M, MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J . 1996; 312 83-88
164 Douketis J D, Ginsberg J S, Holbrook A, Crowther M, Duku E K, Burrows R F. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med . 1997; 157 1522-1530
165 Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet . 1995; 346 1589-1593
166 Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Büller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet . 1995; 346 1593-1596
167 Hellgren M, Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol . 1995; 173 210-213
168 Rintelen C, Mannhalter C, Ireland H. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematology . 1996; 93 487-490
169 Rosing J, Tans G, Nicolaes G AF. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol . 1997; 97 233-238
170 Price D T, Ridker P M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med . 1997; 127 895-903
171 Bloemenkamp K W, Rosendaal F R, Helmerhorst F M, Vandenbroucke J P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med . 2000; 160 49-52
172 Lensen R P, Bertina R M, de Ronde H, Vandenbroucke J P, Rosendaal F R. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost . 2000; 83 817-821
173 Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci P M. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med . 1998; 338 1793-1797
174 Bertina R M, Koeleman B PC, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-67
175 Koster T, Rosendaal F R, de Ronde H, Briet E, Vandenbroucke J P, Bertina R M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet . 1993; 342 1503-1506
176 Sagar S, Stamatakis J D, Thomas D P, Kakkar V V. Oral contraceptives, antithrombin III activity and postoperative deep vein thrombosis. Lancet . 1976; 1 509
177 Belchetz P E. Hormonal treatment of postmenopausal women. N Engl J Med . 1994; 330 1062-1071
178 Koh K K, Horne III K M, Cannon III O R. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women. Thromb Haemost . 1999; 82 626-633
179 van Baal M W, Emeis J J, Van der Mooren J M, Kessel H, Kenemans P, Stehouwer C D. Impaired procoagulant-anticoagulant balance during hormone replacement therapy?. <~>A randomised, placebo-controlled 12-week study. Thromb Haemost . 2000; 83 29-34
180 Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset P M. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the estrogen in venous thromboembolism trial. Blood . 1999; 649a-649a (649a-649a)
181 The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/ progestin interventions (PEPI) trial. JAMA . 1995; 273 199-208
182 Natchigall L E, Natchigall R H, Natchigall R D, Beckman E M. Estrogen replacement therapy, II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol . 1979; 54 74-79
183 Boston Collaborative Drug Surveillance Program BUMC. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med . 1974; 290 15-19
184 Pettiti D B, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women: smoking, oral contraceptives, concontraceptive estrogens, and other factors. JAMA . 1979; 242 1150-1154
185 Devor M, Barrett-Connor E, Renvall M, Feigal Jr D, Ramsdell J. Estrogen replacement and the risk of venous thrombosis. Am J Med . 1992; 92 275-282
186 Jick H, Derby L E, Myers M W, Vasilakis C, Newton K M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet . 1996; 348 981-983
187 Daly E, Vessey M P, Hawkins M N, Carson J L, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet . 1996; 348 977-980
188 Daly E, Vessey M P, Painter R, Hawkins M M. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet . 1996; 348 1027
189 Hoibraaten E, Abdelnoor M, Sandset P M. Hormone replacement therapy with estradiol and risk of venous thromboembolism-a population-based case-control study. Thromb Haemost . 1999; 82 1218-1221
190 Jick H, Stone D, Westerholm B. Venous thromboembolic disease and ABO blood type. Lancet . 1969; 1 539
191 Westerholm B, Wiechel B, Eklund G. Oral contraceptive, venous thromboembolic disease and ABO blood type. Lancet . 1971; 2 664
192 Mourant A E, Kopec A C, Domaniewska-Sobczak K. Blood group and blood clotting. Lancet . 1971; 1 223
193 Wautrecht J C, Galle C, Motte S, Dereume J P, Dramaix M. The role of ABO blood groups in the incidence of deep vein thrombosis. Thromb Haemost . 1998; 79 688-689
194 Koster T, Blann A D, Briet E, Vandenbroucke J P, Rosendaal F R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet . 1995; 345 152-155
195 Lane D A, Mannucci P M, Bauer K A. Inherited thrombophilia: part 1. Thromb Haemost . 1996; 76 651-662
196 Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med . 2000; 51 169-185
197 Monreal M, Ruiz J, Salvador R, Morera J, Arias A. Recurrent pulmonary embolism: A prospective study. Chest . 1989; 95 976-979
198 Van den Belt G M A, Sanson B J, Simioni P. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med . 1997; 157 2227-2232
199 Lane D A, Mannucci P M, Bauer K A. Inherited Thrombophilia: Part 2. Thromb Haemost . 1996; 76 824-834
200 Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood . 1995; 85 1504-1508
201 Tosetto A, Castaman G, Cappelleri A, Rodeghiero F. The VITA project: heritability of resistance to activated protein C. Thromb Haemost . 2000; 84 811-814
202 Chan W P, Lee C K, Kwong Y L, Liang R. A novel mutation of Arg306 of Factor V gene in Hong Kong Chinese. Blood . 1998; 91 1135-1139
203 Mayer E L, Jacobsen D W, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol . 1996; 27 517-527
204 Tosetto A, Missiaglia E, Gatto E, Rodeghiero F. The VITA project: phenotype resistance to activated protein C and FV Leiden mutation in the general population. Thromb Haemost . 1997; 78 859-863
205 de Visser C M, Rosendaal F R, Bertina R M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood . 1999; 93 1271-1276
206 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood . 1996; 88 3698-3703
207 Ridker P M, Hennekens C H, Miletich J P. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke and venous thrombosis in a large cohort of US men. Circulation . 1999; 99 999-1004
208 Margaglione M, Brancaccio V, Giuliani N. Increased risk for venous thrombosis in carriers of the prothrombin G-a 20210 gene variant. Ann Intern Med . 1998; 129 89-93
209 Leroyer C, Mercier B, Oger E. Prevalence of 20210A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost . 1998; 80 49-51
210 Simioni P, Tormene D, Manfrin D. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol . 1998; 103 1045-1050
211 Kraaijenhagen R A, in't Anker S P, Koopman M M. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost . 2000; 83 5-9
212 Rosendaal F R. High levels of factor VIII and venous thrombosis. Thromb Haemost . 2000; 83 1-2
213 Kryle P, Minar E, Hirschl M. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med . 2000; 343 457-462
214 Meijers J C, Tekelenburg W L, Bouma B N, Bertina R M, Rosendaal F R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med . 2000; 342 696-701
215 Koster T, Rosendaal F R, Reitsma P H, van der Velden A P, Briet E, Vandenbroucke J P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS). Thromb Haemost . 1994; 71 719-722
216 Brandt J T, Barna L K, Triplett D A. Laboratory identification of lupus anticoagulants: results of the second international workshop for identification of lupus anticoagulants. Thromb Haemost . 1995; 74 1597-1603
217 Harris E N. The second international anti-cardiolipin standardization workshop/the Kingston anti-phospholipid antibody study (KAPS) group. Am J Clin Pathol . 1990; 94 476-484
218 Greaves M. Antiphospholipid antibodies and thrombosis. Lancet . 1999; 353 1348-1353
219 Wahl D G, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus . 1998; 7 15-22
220 Wahl D G, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus . 1997; 6 467-473
221 Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med . 1998; 104 332-338
222 Rosove M H, Brewer P MC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med . 1992; 117 303-308
223 Vianna J L, Khamashta M A, Ordi-Ros J. Comparison of the primary and secondary antiphospholipid syndrome: a European multicentre study of 114 patients. Am J Med . 1994; 96 3-9
224 Khamashta M A, Cuadrado M J, Mujic F, Taub N A, Hunt B J, Hughes G RV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med . 1995; 332 993-997
225 Ginsberg J S, Wells P S, Brill-Edwards P. Antiphospholipid antibodies and venous thromboembolism. Blood . 1995; 86 3685-3691
226 Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost . 1996; 75 859
227 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost . 1999; 81 165-176
228 Eichinger S, Stumpflen A, Hirschl M. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost . 1998; 80 566-569
229 Eekhoff E M, Rosendaal F R, Vandenbroucke J P. Minor events and the risk of deep venous thrombosis. Thromb Haemost . 2000; 83 408-411
230 Kawasaki T, Kambayashi J, Sakon M. Hyperlipidemia: a novel etiologic factor in deep vein thrombosis. Thromb Res . 1995; 79 147-151
231 Socie G, Mary J Y, de Gramont A. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet . 1996; 348 573-577
232 Long A A, Ginsberg J S, Brill-Edwards P. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost . 1991; 66 520-524
233 Katsumura Y, Ohtsubo K-I. Incidence of pulmonary thromboembolism, infarction and haemorrhage in disseminated intravascular coagulation: a necroscopic analysis. Thorax . 1995; 50 160-164
234 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med . 1995; 332 1330-1335
235 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost . 1998; 79 1-7
236 Nilsson I M, Krook H, Stermby N H. Severe thrombotic disease in a young man with a high content of an inhibitor in the fibrinolytic system. Acta Med Scand . 1961; 169 323
237 Johansson L, Hedner U, Nilsson I M. A family with thromboembolic disease and associated with deficient fibrinolytic activity in vessel wall. Acta Med Scand . 1978; 203 477
238 Koenigs K P, McPhedran P, Spiro H M. Thrombosis in inflammatory bowel disease. J Clin Gastroenterol . 1987; 9 617-621
239 Talbot R W, Heppell J, Dozois R R, Beart R W. Vascular complications of inflammatory bowel disease. Mayo Clin Proc . 1986; 61 140-145
240 Franco R F, Reitsma P H, Lourenco D. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost . 1999; 81 676-679
241 Rosendaal F R. Venous thrombosis: a multicausal disease. Lancet . 1999; 353 1167-1173
242 Miletich J P. Thrombophilia as a multigenic disorder. Semin Thromb Haemost . 1998; 24 13-20
243 DeStefano V, Chiusolo P, Paciaroni K. Prevalence of the factor II G20210A mutation in symptomatic patients with inherited thrombophilia. Thromb Haemost . 1998; 80 342-343
244 Makris M, Preston F E, Beauchamp N J. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost . 1997; 78 1426-1429
245 Gandrille S, Greengard J S, Alhenc-Gelas M. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood . 1995; 86 219-224
246 Zoller B, Holm J, Svensson P, Dahlback B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost. 1980;
247 Van Boven H H, Reitsma P H, Rosendaal F R. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 1996; 75 417-421
248 Bovill E G, Hasstedt S J, Callas P W. The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred. Thromb Haemost . 2000; 83 366-370
249 Alhenc-Gelas M, Arnaud E, Nicaud V. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost . 1999; 81 506-510
250 Van den Belt G M A, Huisman M V, Hirsh J. Familial thrombophilia: a review analysis. Clin Appl Thromb Hemost . 1996; 2 227-236
251 Simioni P, Sanson B J, Prandoni P. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost . 1999; 81 198-202
252 Bjorgell O, Nilsson P E, Nilsson J A, Svensson P J. Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation. Thromb Haemost . 2000; 83 648-651
253 Wells P S, Anderson D R, Kearon M C, Weitz J I, Hirsh J. The combination of pretest clinical likelihood (PCL) and non-invasive tests improves management of outpatients with suspected deep vein thrombosis (DVT). Thromb Haemost . 1993; 69 1080
254 Papinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III, protein C and protein S deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost . 1994; 71 548-552
255 Greer I A. Thrombosis in pregnancy: maternal and fetal issues. Lancet . 1999; 353 1258-1265
256 Lindqvist P G, Svensson P J, Marsal K, Grennet L, Luterkort M, Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost . 1999; 81 532-537
257 Conard J, Horellou M H, Van Dreden P. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C, or protein S: study of 78 women. Thromb Haemost . 1990; 63 319-330
258 DeStephano V, Leone G, Mastrangelo S. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost . 1994; 71 799-800
259 Bloemenkamp K W, Helmerhorst F M, Rosendaal F R, Vandenbroucke J P. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost . 1999; 82 1024-1027
260 Lowe G DO, Haverkate F, Thompson S G. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT study. Thromb Haemost . 1999; 81 879-886
261 Svensson P J, Benoni G, Fredin H. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty. Thromb Haemost . 1997; 78 993-996
262 Ridker P M, Hennekens C H, Selhub J, Miletich J P, Malinow M R, Stampfer M J. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation . 1997; 95 1777-1782
263 Joffe S N. Racial incidence of postoperative deep vein thrombosis in South Africa. Br J Surg . 1974; 61 982
264 Nicolaides A N, Field E S, Kakkar V V. Prostatectomy and deep vein thrombosis. Br J Surg . 1972; 59 487
265 Bern M M, Lokich J J, Wallach S R. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med . 1990; 112 423-428
266 Trottier S J, Veremakis C, O'Brien J, Auer A I. Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial. Crit Care Med . 1995; 23 52-59
267 Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg . 1978; 49 378-381
268 Quinn D A, Thompson T, Terrin M. A prospective evaluation of pulmonary embolism in men and women. JAMA . 1992; 268 1689-1696
269 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet . 1995; 346 1582-1588
270 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and oral contraceptives: results of international multicentre case-control study. Lancet . 1995; 246 1575-1582